Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials
Fred Yang,1 June Ye,2 Kenneth Pomerantz,3 Murray Stewart1 1Alternative Development Program, GlaxoSmithKline, King of Prussia, PA, 2Discovery Biometrics, GlaxoSmithKline, Research Triangle Park, NC, 3Clinical Development and Medical Affairs, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT,...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2013
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/912265badf8e4dbb897f67b8f1ac6522 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|